We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...

Amar Vennapusa, a bariatric surgeon, fills a syringe with Eli Lilly's Mounjaro, a tirzepatide injection drug used for ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Key Takeaways Pfizer said it will discontinue development of oral daily weight-loss treatment danuglipron.A Phase 3 trial ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek more accessible treatment options ...

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...